Blueprint Medicines Valuation
| BPMC Stock | USD 93.08 2.19 2.30% |
At this time, the firm appears to be undervalued. Blueprint Medicines Corp shows a prevailing Real Value of $97.12 per share. The current price of the firm is $93.08. Our model approximates the value of Blueprint Medicines Corp from analyzing the firm fundamentals such as Return On Equity of -0.31, current valuation of 5.94 B, and Profit Margin of (0.13) % as well as examining its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that Blueprint Medicines' price fluctuation is very steady at this time. Calculation of the real value of Blueprint Medicines Corp is based on 3 months time horizon. Increasing Blueprint Medicines' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Blueprint Medicines is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Blueprint Stock. However, Blueprint Medicines' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 93.08 | Real 97.12 | Hype 93.08 |
The real value of Blueprint Stock, also known as its intrinsic value, is the underlying worth of Blueprint Medicines Corp Company, which is reflected in its stock price. It is based on Blueprint Medicines' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Blueprint Medicines' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Blueprint Medicines Corp helps investors to forecast how Blueprint stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Blueprint Medicines more accurately as focusing exclusively on Blueprint Medicines' fundamentals will not take into account other important factors: Blueprint Medicines Total Value Analysis
Blueprint Medicines Corp is currently expected to have valuation of 5.94 B with market capitalization of 6.09 B, debt of 126.05 M, and cash on hands of 853.11 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Blueprint Medicines fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
5.94 B | 6.09 B | 126.05 M | 853.11 M |
Blueprint Medicines Investor Information
About 99.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 1.07. Blueprint Medicines Corp had not issued any dividends in recent years. Based on the key indicators related to Blueprint Medicines' liquidity, profitability, solvency, and operating efficiency, Blueprint Medicines Corp is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April.Blueprint Medicines Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Blueprint Medicines has an asset utilization ratio of 43.13 percent. This indicates that the Company is making $0.43 for each dollar of assets. An increasing asset utilization means that Blueprint Medicines Corp is more efficient with each dollar of assets it utilizes for everyday operations.Blueprint Medicines Ownership Allocation
The majority of Blueprint Medicines Corp outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Blueprint Medicines Corp to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Blueprint Medicines. Please pay attention to any change in the institutional holdings of Blueprint Medicines Corp as this could imply that something significant has changed or is about to change at the company.Blueprint Medicines Profitability Analysis
The company reported the previous year's revenue of 508.82 M. Net Loss for the year was (67.09 M) with profit before overhead, payroll, taxes, and interest of 488.66 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Blueprint Medicines' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Blueprint Medicines and how it compares across the competition.
About Blueprint Medicines Valuation
The stock valuation mechanism determines Blueprint Medicines' current worth on a weekly basis. Our valuation model uses a comparative analysis of Blueprint Medicines. We calculate exposure to Blueprint Medicines's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Blueprint Medicines's related companies.Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts. Blueprint Medicines operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 580 people.
Blueprint Medicines Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 62.9 M |
Complementary Tools for Blueprint Stock analysis
When running Blueprint Medicines' price analysis, check to measure Blueprint Medicines' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Blueprint Medicines is operating at the current time. Most of Blueprint Medicines' value examination focuses on studying past and present price action to predict the probability of Blueprint Medicines' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Blueprint Medicines' price. Additionally, you may evaluate how the addition of Blueprint Medicines to your portfolios can decrease your overall portfolio volatility.
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |